Jonathan W Simons

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer
    Jonathan W Simons
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Urol Oncol 24:419-24. 2006
  2. ncbi request reprint Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells
    Ceshi Chen
    Winship Cancer Institute and Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Biol Chem 280:41553-61. 2005
  3. ncbi request reprint Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
    Xiaodong Sun
    Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Nat Genet 37:407-12. 2005
  4. doi request reprint Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells
    TISHEEKA R GRAHAM
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Cancer Res 68:2479-88. 2008
  5. ncbi request reprint KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line
    Ceshi Chen
    Winship Cancer Institute and Department of Oncology and Hematology, Emory University School of Medicine, Atlanta, GA, USA
    Int J Cancer 118:1346-55. 2006
  6. doi request reprint Quantum dots: emerging applications in urologic oncology
    Chunmeng Shi
    Molecular Urology and Therapeutics Program, Department of Urology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Urol Oncol 26:86-92. 2008
  7. ncbi request reprint Nanotechnology for targeted cancer therapy
    May D Wang
    Georgia Institute of Technology, Department of Biomedical Engineering, and Emory University, Atlanta, GA 30332, USA
    Expert Rev Anticancer Ther 7:833-7. 2007
  8. ncbi request reprint Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model
    Seung Hee Kang
    Department of Hematology Oncology, Emory University, School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 66:11991-7. 2006
  9. ncbi request reprint Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer
    Jonathan W Simons
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 12:3394-401. 2006
  10. ncbi request reprint Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells
    Nicola J Mabjeesh
    Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 9:2416-25. 2003

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer
    Jonathan W Simons
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Urol Oncol 24:419-24. 2006
    ..Multi-institutional phase III investigation is currently underway to evaluate the impact of allogeneic prostate GVAX cellular immunotherapy on time to progression and overall survival in hormone refractory prostate cancer...
  2. ncbi request reprint Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells
    Ceshi Chen
    Winship Cancer Institute and Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Biol Chem 280:41553-61. 2005
    ..These findings not only established WWP1 as an E3 ubiquitin ligase for KLF5, they also further implicated the KLF5 pathway in human carcinogenesis...
  3. ncbi request reprint Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
    Xiaodong Sun
    Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Nat Genet 37:407-12. 2005
    ..Furthermore, ATBF1 inhibited cell proliferation. Hence, loss of ATBF1 is one mechanism that defines the absence of growth control in prostate cancer...
  4. doi request reprint Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells
    TISHEEKA R GRAHAM
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Cancer Res 68:2479-88. 2008
    ..These results identify ZEB1 as a key transcriptional regulator of EMT in prostate cancer and suggest that the aberrant expression of ZEB1 in prostate cancer cells occurs in part in response to IGF-I stimulation...
  5. ncbi request reprint KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line
    Ceshi Chen
    Winship Cancer Institute and Department of Oncology and Hematology, Emory University School of Medicine, Atlanta, GA, USA
    Int J Cancer 118:1346-55. 2006
    ..These findings suggest that the KLF5 transcription factor plays an oncogenic role in the TSU-Pr1 bladder cancer cell line through the regulation of a subset of genes...
  6. doi request reprint Quantum dots: emerging applications in urologic oncology
    Chunmeng Shi
    Molecular Urology and Therapeutics Program, Department of Urology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Urol Oncol 26:86-92. 2008
    ..In this article, we describe the development of multifunctional QDs and their potential applications in oncology, with a particular emphasis on the diagnosis, prognosis, and treatment of urologic cancers...
  7. ncbi request reprint Nanotechnology for targeted cancer therapy
    May D Wang
    Georgia Institute of Technology, Department of Biomedical Engineering, and Emory University, Atlanta, GA 30332, USA
    Expert Rev Anticancer Ther 7:833-7. 2007
    ....
  8. ncbi request reprint Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model
    Seung Hee Kang
    Department of Hematology Oncology, Emory University, School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 66:11991-7. 2006
    ....
  9. ncbi request reprint Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer
    Jonathan W Simons
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 12:3394-401. 2006
    ....
  10. ncbi request reprint Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells
    Nicola J Mabjeesh
    Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 9:2416-25. 2003
    ..Experimental Design: Androgen and antiandrogen effects were evaluated on HIF-1alpha protein and HIF-1 transcriptional activation in human PCA cells...
  11. ncbi request reprint Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis
    Hua Zhong
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University, 1365 B Clifton Road, N E Room B4328, Atlanta, GA 30322, USA
    Cancer Detect Prev 28:88-93. 2004
    ....
  12. ncbi request reprint Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells
    Ceshi Chen
    Department of Oncology and Hematology, Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Road, Atlanta, GA, USA
    Oncogene 24:3319-27. 2005
    ..These results suggest that KLF5 protein is degraded at least in part through ubiquitination-proteasome pathway, which may have become hyperactive for KLF5 in cancer cells...
  13. ncbi request reprint Novel therapeutic strategies for androgen-independent prostate cancer: an update
    Vasily J Assikis
    Winship Cancer Institute Prostate Cancer Translational Research Program, Emory University, Atlanta, GA 30322, USA
    Semin Oncol 31:26-32. 2004
    ..Such new therapeutic modalities, along with recent data on immunotherapy and bone targeting strategies, will be reviewed here...
  14. ncbi request reprint Nanotechnology applications in cancer
    Shuming Nie
    Department of Biomedical Engineering and the Winship Cancer Institute, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA
    Annu Rev Biomed Eng 9:257-88. 2007
    ..These developments raise exciting opportunities for personalized oncology in which genetic and protein biomarkers are used to diagnose and treat cancer based on the molecular profiles of individual patients...
  15. ncbi request reprint 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
    Nicola J Mabjeesh
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer Cell 3:363-75. 2003
    ..These data establish 2ME2 as a small molecule inhibitor of HIF-1 and provide a mechanistic link between the disruption of the MT cytoskeleton and inhibition of angiogenesis...
  16. ncbi request reprint Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry
    Yun Xing
    Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 101 Woodruff Circle Suite 1001, Atlanta, Georgia 30322, USA
    Nat Protoc 2:1152-65. 2007
    ..In general, QD bioconjugation is completed within 1 day, and multiplexed molecular profiling takes 1-3 days depending on the number of biomarkers and QD probes used...
  17. ncbi request reprint Exploitation of the HIF axis for cancer therapy
    Daniel Escuin
    Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Cancer Biol Ther 3:608-11. 2004
    ..We will overview inhibitors of HIF-1alpha and will discuss their potential use for cancer therapy...
  18. ncbi request reprint Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells
    Nicola J Mabjeesh
    Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 62:2478-82. 2002
    ..Thus, benzoquinone ansamycin drugs and their derivatives, such as 17-allyl-aminogeldanamycin, are excellent candidates as small molecule drug inhibitors of HIF-1 overexpression in cancer cells...
  19. ncbi request reprint Dibenzoylmethane, a natural dietary compound, induces HIF-1 alpha and increases expression of VEGF
    Nicola J Mabjeesh
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 B Clifton Road, Atlanta, GA 30322, USA
    Biochem Biophys Res Commun 303:279-86. 2003
    ..Mechanistically, HIF-1 alpha was stabilized by DBM at a step prior to ubiquitination. The effect of DBM on HIF-1 and its low toxicity profile might be therapeutically beneficial in ischemic diseases...
  20. ncbi request reprint HIF at the crossroads between ischemia and carcinogenesis
    Stefan A M Paul
    Department of Internal Medicine I, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    J Cell Physiol 200:20-30. 2004
    ..The consequences of the switch of HIF activation in these two disease states and the signaling pathway overlap that atherosclerosis and cancer angiogenesis share are discussed...
  21. doi request reprint Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
    Celestia S Higano
    Department of Oncology, University of Washington Seattle, Seattle, Washington, USA
    Cancer 113:975-84. 2008
    ..The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate-carcinoma cell lines modified to secrete granulocyte-macrophage-colony-stimulating factor (GM-CSF)...
  22. ncbi request reprint MSF-A interacts with hypoxia-inducible factor-1alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis
    Sharon Amir
    Prostate Cancer Research Laboratory, Department of Urology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 64239 Tel Aviv, Israel
    Cancer Res 66:856-66. 2006
    ..Xenograft-derived human tumors from these cells were larger and more vascular. These findings link a function of a septin protein with angiogenesis through activation of the HIF pathway...
  23. ncbi request reprint Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
    Eric J Small
    University of California, San Francisco, Comprehensive Cancer Center, San Francisco, California 94115, USA
    Clin Cancer Res 13:3883-91. 2007
    ..The immunotherapy, based on the GVAX platform, is a combination of two prostate carcinoma cell lines modified with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene...